NovoCure Limited [NASDAQ: NVCR] closed the trading session at $148.90 on 02/25/21. The day’s price range saw the stock hit a low of $141.79, while the highest price level was $171.0078. The company report on February 25, 2021 that Novocure Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update.
Quarterly net revenues of $144.0 million, representing 45 percent growth versus the fourth quarter 2019 and 9 percent growth versus the third quarter 2020.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Quarterly net income of $4.9 million with $0.05 in earnings per share.
The stocks have a year to date performance of -13.95 percent and weekly performance of -15.26 percent. The stock has been moved at 86.08 percent over the last six months. The stock has performed -9.51 percent around the most recent 30 days and changed 10.78 percent over the most recent 3-months.
If compared to the average trading volume of 926.47K shares, NVCR reached to a volume of 1657847 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about NovoCure Limited [NVCR]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVCR shares is $150.13 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVCR stock is a recommendation set at 2.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Piper Sandler have made an estimate for NovoCure Limited shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 25, 2021. While these analysts kept the previous recommendation, Northland Capital raised their target price to Outperform. The new note on the price target was released on September 23, 2020, representing the official price target for NovoCure Limited stock. Previously, the target price had yet another raise to $116, while Wells Fargo analysts kept a Equal Weight rating on NVCR stock.
The Average True Range (ATR) for NovoCure Limited is set at 11.96, with the Price to Sales ratio for NVCR stock in the period of the last 12 months amounting to 31.15. The Price to Book ratio for the last quarter was 49.14, with the Price to Cash per share for the same quarter was set at 2.49. Price to Free Cash Flow for NVCR in the course of the last twelve months was 347.53 with Quick ratio for the last quarter at 3.70.
NVCR stock trade performance evaluation
NovoCure Limited [NVCR] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -15.26. With this latest performance, NVCR shares dropped by -9.51% in over the last four-week period, additionally plugging by 86.08% over the last 6 months – not to mention a rise of 87.41% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NVCR stock in for the last two-week period is set at 34.86, with the RSI for the last a single of trading hit 28.10, and the three-weeks RSI is set at 39.84 for NovoCure Limited [NVCR]. The present Moving Average for the last 50 days of trading for this stock 170.96, while it was recorded at 173.24 for the last single week of trading, and 112.42 for the last 200 days.
NovoCure Limited [NVCR]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and NovoCure Limited [NVCR] shares currently have an operating margin of -0.17 and a Gross Margin at +74.87. NovoCure Limited’s Net Margin is presently recorded at -2.06.
Return on Total Capital for NVCR is now -0.18, given the latest momentum, and Return on Invested Capital for the company is -2.25. Return on Equity for this stock declined to -4.38, with Return on Assets sitting at -1.77. When it comes to the capital structure of this company, NovoCure Limited [NVCR] has a Total Debt to Total Equity ratio set at 77.23. Additionally, NVCR Total Debt to Total Capital is recorded at 43.58, with Total Debt to Total Assets ending up at 35.08. Long-Term Debt to Equity for the company is recorded at 75.10, with the Long-Term Debt to Total Capital now at 42.38.
Reflecting on the efficiency of the workforce at the company, NovoCure Limited [NVCR] managed to generate an average of -$9,246 per employee. Receivables Turnover for the company is 6.32 with a Total Asset Turnover recorded at a value of 0.86.NovoCure Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 4.00.
Earnings per share (EPS) analysis for NovoCure Limited [NVCR] stock
With the latest financial reports released by the company, NovoCure Limited posted 0.04/share EPS, while the average EPS was predicted by analysts to be reported at 0.02/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVCR.
NovoCure Limited [NVCR]: Insider Ownership positions
There are presently around $10,898 million, or 73.40% of NVCR stock, in the hands of institutional investors. The top three institutional holders of NVCR stocks are: FMR LLC with ownership of 9,627,554, which is approximately -3.302% of the company’s market cap and around 0.70% of the total institutional ownership; BAILLIE GIFFORD & CO, holding 8,261,075 shares of the stock with an approximate value of $1.23 billion in NVCR stocks shares; and CAPITAL INTERNATIONAL INVESTORS, currently with $1.23 billion in NVCR stock with ownership of nearly 0.692% of the company’s market capitalization.
Positions in NovoCure Limited stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 221 institutional holders increased their position in NovoCure Limited [NASDAQ:NVCR] by around 6,871,758 shares. Additionally, 120 investors decreased positions by around 6,094,371 shares, while 41 investors held positions by with 60,222,200 shares. The mentioned changes placed institutional holdings at 73,188,329 shares, according to the latest SEC report filing. NVCR stock had 102 new institutional investments in for a total of 1,380,970 shares, while 33 institutional investors sold positions of 1,986,942 shares during the same period.